FLT1 and neoplasm: Tivozanib is a potent and highly selective oral inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 (VEGFR-1, -2, and -3), making it a promising anti-angiogenic agent for solid tumors, particularly renal cell carcinoma (RCC).82 By blocking VEGF-mediated signaling, tivozanib effectively reduces tumor vascularization and progression.